Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc ONCY


Primary Symbol: T.ONC

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by Noteableon Oct 14, 2024 12:41pm
62 Views
Post# 36265294

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:CD8+ TiLs and T-cell exhaustion

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:CD8+ TiLs and T-cell exhaustionUnlike atezolizumab, pela’s clinical activity was lost when combined with avelumab, a PD-LI inhibitor with a native Fc region that is capable of binding Fc receptors and inducing ADCC. The addition of avelumab eliminated pre-existing TIL expansion in the blood highlighting the importance of TIL expansion following pela therapy.

The same elimination of pre-existing TILs and TILs expansion in the blood does not happen when ONCY's pelareorep is combined with other ICIs.  Instead the addition of pelareorep results in the remodeling of an mmunosuppressive TME and the the priming of the immune systems.

The result is TME - T-cell expansion that prepares the TME for the synergistic addition of ICI's like atezolizumab and pembrolizumab, and other Fc de-activated ICIs, other than those like Bavencio (avelumab).
<< Previous
Bullboard Posts
Next >>